What Компламин Treats: Main Uses and Benefits

The primary therapeutic utility of Компламин (Xantinol Nicotinate) is considered relevant for providing supportive management for conditions driven by impaired circulation, focusing on the symptomatic discomfort experienced across key vascular domains. The application of this compound includes addressing symptoms related to both peripheral and cerebral vascular disorders.

This medication is applied across domains where additional symptomatic support is needed in conditions like Peripheral Vascular Disease (PVD) and Raynaud's Phenomenon, or when there are signs of Cerebrovascular Insufficiency. It helps address symptom clusters that interfere with daily comfort, such as the pain of intermittent claudication, chronic cramping, numbness, persistent cold extremities, and dizziness. The use is intended to assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes.

“The therapeutic role is generally considered to involve supportive relief that helps patients cope more steadily with symptom fluctuations associated with poor circulation.”

Quick Fact: Relief for Ischemic Limb Pain

Компламин is relevant for easing symptoms that create noticeable physiological strain, including severe rest pain and early-stage cyanotic changes in the extremities. It provides support that helps ease the overall symptom burden in scenarios where symptoms escalate temporarily, contributing to easing the overall symptom load during periods of heightened discomfort.

The eligibility profile for Компламин (Xantinol Nicotinate) is defined by official regulatory documentation, which outlines populations for whom the medicine is strictly prohibited, restricted, or allowed.

Populations for Whom Use is Prohibited (Contraindications)

Individuals must not use this medicine if they have:

• A known allergy or hypersensitivity to Xantinol Nicotinate or its components.
• An acute cardiovascular event, such as acute myocardial infarction (heart attack) or acute heart failure.
• Acute hemorrhage or severe bleeding disorders.
• Severe conditions such as severe arterial hypotension (very low blood pressure) or glaucoma.

Restricted and Conditional Use

Condition	Regulatory Status	Restriction
Age	Contraindicated	Use is prohibited in children and adolescents (typically under 18 years) as safety is not established.
Pregnancy	Contraindicated/Conditional	Prohibited during the first trimester; conditional use only during the second and third trimesters if potential benefit outweighs risk.
Comorbidities	Caution Required	Use requires caution and close monitoring in patients with chronic heart failure, chronic renal impairment, non-severe hypotension, or active peptic ulcer disease.
Lactation	Not Recommended	Use is not recommended while breastfeeding; cessation of breastfeeding is typically required if treatment is necessary.

Interactions with other medicines and products

Interaction Entity Map (Official Regulatory Profile)

The official interaction profile for Xantinol Nicotinate is defined primarily by its classification as a peripheral vasodilator, which leads to pharmacodynamic reinforcement with other agents that lower blood pressure. The regulatory profile contains no explicit documentation of pharmacokinetic interactions involving specific CYP-enzymes or drug transporters.

Category	Interacting Substance / Product	Interaction Type Classification	Formal Interaction Outcome
Pharmacodynamic Interaction	Antihypertensive Medications	Pharmacodynamic (Additive Effect)	Increased risk of hypotension (low blood pressure)
Drug–Substance Interaction	Alcohol (Ethanol)	Pharmacodynamic (Additive Effect)	May enhance the risk of hypotension

Interaction-Related Restrictions

Co-administration with Antihypertensive Medications is documented to result in a clinically significant pharmacodynamic interaction, necessitating use with caution due to the risk of enhanced hypotension. The interaction profile also includes a documented risk that co-consumption of alcohol may contribute to this increased hypotensive effect.

Official regulatory documents do not specify mandatory timing separation rules for administration, nor do they document specific interactions with food, herbal products, or dietary supplements.

Dual Modulation of Vascular Smooth Muscle Tone

The mechanism centers on simultaneous activation of two distinct pathways to induce peripheral vasodilation. The Nicotinic Acid moiety acts as an agonist at the HCAR2 receptor, while the Xanthinol moiety acts as an inhibitor of the Phosphodiesterase (PDE) enzyme. Both actions converge to reduce the contractile state of the smooth muscle surrounding blood vessels, inducing peripheral vasodilation.

---

Modulation of Cellular Bioenergetics

The second primary mechanism involves modulating tissue energy generation. The Nicotinic Acid component serves as a precursor to the essential metabolic coenzymes NAD and NADP, which are required to maintain the efficiency of tissue respiration pathways (Glycolysis and the Krebs Cycle). This action leads to increased cellular ATP concentration, which modulates red blood cell deformability and influences overall capillary perfusion and oxygen delivery at the tissue level.

---

Mechanistic Synergy

The two components exhibit mechanistic synergy. The dual vascular mechanism induces vessel widening, and the metabolic mechanism modulates the energy dynamics of the receiving tissues, resulting in a combined physiological action involving both vascular and metabolic pathways.

The administration of Компламин (Xantinol Nicotinate) is defined by a dual-route protocol, utilizing both the Oral tablet form for maintenance and the Parenteral solution for injection, often via the intravenous (IV) route, for acute or initial treatment courses.

---

Labeled Dosing and Administration

The documented adult oral regimen ranges from 300 mg to 600 mg per dose and is usually scheduled two to three times a day. The total daily oral intake does not exceed the maximum dose of 3 g (3000 mg). The injection solution is reserved for administration in a clinical/hospital setting, where it is diluted and administered as a controlled slow intravenous infusion by a qualified professional.

Procedural Constraints

Specific rules govern the intake of the oral form. Tablets, particularly those with an extended-release profile, are swallowed whole and are not crushed or chewed. Additionally, the oral dose is directed to be taken immediately after meals with liquid. These time-specific and handling constraints are standard for proper administration. The protocol for a missed oral dose involves skipping the dose if it is close to the time for the next scheduled dose, thereby avoiding dose doubling. The overall protocol establishes a procedural sequence from acute parenteral use to long-term oral maintenance.

Research Evidence / Overview of Studies for Компламин (Xantinol Nicotinate)

---

Research Evidence for Peripheral Vascular Disorders

Xantinol Nicotinate was studied for conditions characterized by functional limitations, particularly those involving reduced blood flow in the extremities. The evidence base includes controlled clinical trials, some of which were double-blind, as well as prospective observational studies. Studies primarily involved adults with chronic lower limb ischemia or severe, progressive issues where blood vessel narrowing was present.

Applied in research exploring how symptoms change over time, studies monitored outcomes related to physical discomfort, such as changes in the distance a person could walk before experiencing pain (intermittent claudication) and the severity of rest pain. Researchers also examined objective outcomes, including changes in physiological measures like the Ankle Brachial Pressure Index (ABPI). Data show patterns related to symptomatic and physiological outcomes, often within a short-term observation interval.

---

Research Evidence for Cerebrovascular Symptoms and Cognitive Function

Xantinol Nicotinate was studied for conditions associated with functional limitations and symptoms linked to cerebral blood flow, particularly in older patients. Research examined outcomes related to systemic or functional imbalance, including assessments of general intellectual capacity using specific rating scales. Reports from drug monitoring programs described how target symptoms evolved in large patient cohorts.

---

Quality of the Evidence and Areas of Uncertainty

The evidence base consists of controlled trials from various time periods, and its quality varies across studies. Many of the core findings rely on trials considered historical. This means that sample sizes were modest in several key studies, and the methodological rigor may not meet current regulatory expectations for new drug approval.

There is a significant gap in the evidence base due to the lack of large-scale, modern Randomized Controlled Trials designed with contemporary diagnostic tools and long-term follow-up protocols. Long-term effects are not fully established, and data for certain subgroups, such as specific diabetic groups, remain insufficient. Research provides context but does not determine whether an individual will respond similarly.

Common questions about Компламин (FAQ)

---

Q: Can Complamin cause dry mouth or increased thirst?

Official prescribing information indicates that dry mouth and increased thirst are among the possible side effects reported with this medication. If these or any other unexpected effects are experienced, such experiences may warrant professional consultation or review of the official prescribing information.

---

Q: How does Complamin interact with blood thinning medications (anticoagulants)?

While the full regulatory profile may not explicitly list every interaction, components related to Xantinol Nicotinate may influence blood coagulation. The concurrent use of agents that slow blood clotting, such as anticoagulants, may increase the potential for bruising or bleeding. Due to the potential for interaction, the concurrent use of these agents necessitates professional oversight.

---

Q: Is Complamin used to treat Raynaud's disease?

Complamin’s pharmacological classification describes its use in conditions involving impaired blood flow in the peripheral blood vessels. Raynaud’s disease, which is characterized by reduced circulation in the extremities, falls within the general therapeutic scope related to the drug’s primary action of improving peripheral circulation.

---

Q: Can Complamin be used for migraines?

The mechanism of action of Complamin involves inducing vasodilation, which affects cerebral circulation (blood flow to the brain). Regulatory contexts or available data describe the use of the medication in certain cases related to migraine management due to this physiological action.

---

Q: Can Complamin cause weight gain?

According to the established safety profile and available product information, Complamin is not typically associated with changes in body weight. However, if a user experiences unexpected weight fluctuation, this may warrant professional consultation.

---

Q: Can Complamin affect the menstrual cycle?

The regulatory safety documentation does not establish a link between the use of Complamin and changes to the menstrual cycle. Any alterations that occur during treatment may warrant professional consultation.

---

Q: Does Complamin affect the ability to drive or operate machinery?

Complamin may cause side effects such as headache, dizziness, or nausea, as listed in the official safety profile. These effects could potentially impair concentration and the ability to operate vehicles or complex machinery safely. Due to these potential effects, exercising caution or temporarily refraining from these activities may be appropriate until the effect of the medicine is known.

---

Q: What are the cerebrovascular disorders for which Complamin is prescribed?

Cerebrovascular disorders are conditions related to the blood flow to the brain (cerebral circulation). The drug’s purpose is defined by its action to induce vasodilation, which is associated with improving circulation in situations where the blood flow to the brain is compromised, such as in cases of cerebrovascular insufficiency.

---

Q: Can Complamin cause increased heart rate (palpitations)?

Official adverse reaction lists state that increased heart rate (tachycardia) and palpitations are possible side effects of Complamin. These reactions are generally considered related to the drug’s vasodilatory effect on the vascular system.

---

Q: In what context is Complamin use mentioned in the treatment of trophic ulcers?

The mechanism of action of Complamin involves inducing vasodilation, which aims to enhance peripheral blood flow and microcirculation in tissues. This action, related to improved local circulation and nutrient delivery, is considered a relevant physiological factor in the treatment context of conditions like trophic ulcers.

---

Q: How does Complamin affect cholesterol levels?

The active component of Complamin is a derivative of Nicotinic Acid (Niacin). Niacin is known to influence the body’s metabolism of fats, including levels of cholesterol (LDL and HDL) and triglycerides. This influence may be part of the drug’s overall metabolic effect, though Complamin is not primarily classified or used as a core cholesterol-lowering medication.

How to Store and Dispose of Компламин (Xantinol Nicotinate)?

Storage and disposal must strictly follow official regulatory requirements to maintain product quality and safety.

---

Storage Conditions

Компламин must be stored at a temperature not exceeding 25°C. To ensure protection from light, the medicine must be kept in its original package. As a mandatory safety measure, the product must be stored out of the sight and reach of children.

Disposal Instructions

Do not use the medicine past the expiry date printed on the packaging. Unused or expired Компламин should not be disposed of in wastewater (flushed down a toilet or sink). Official guidance recommends utilizing local drug take-back programs or following the approved household method of mixing the medicine with an undesirable substance in a sealed container before discarding it in the trash.